Pharmaceutical AstraZeneca is considering conducting “additional research” to confirm the results. the effectiveness of the coronavirus vaccine after it was discovered that unexpected dosage changes had occurred during the first trial, firm CEO Pascal Sorio said Thursday.
The head of a pharmaceutical company that partnered with Oxford University to develop a vaccine told Bloomberg that don’t expect these new tests to delay approval from the health authorities of the UK and the European Union.
This week, AstraZeneca and Oxford released preliminary results from their third phase of a clinical trial divided into two patient groups. One group received two full doses of the vaccine with a 62% efficacy result., while the other received half the dose and a month later the full dose, a method that was 90% effective.
Oxford admitted on Thursday that not originally planned to vaccinate half the dose any patient, but this was the result of an error in the preparation process. As soon as it was discovered that the first vaccine shipment had begun to be inoculated at a concentration lower than planned, it was decided: change research protocolThis is stated in the message of the university, said in the message of the sanitary “regulator”.
“Now that we’ve found what appears to be more effective, we need to test it out, so we need to do more research,” Sorio said. The CEO explained that he is likely to new “international study”, although he assured that “it may be faster” than previous ones, because the researchers already know that the vaccine is “high” and they need “fewer patients.”
He also stressed that permission to start vaccinations in some countries is still planned for the end of the year, although in the United States, this process will take longerbecause the tests were carried out outside this country.
According to the Financial Times, the head of the US vaccine development program, Moncef Sloughi, said on the 24th that the subset of only 2,300 people that received the most effective dose was limited to smaller people. 55 years old, with a lower risk of developing severe symptoms of coronavirus – data that neither the university nor AstraZeneca disclosed when submitting their data.